Circulating Tumor Cell Count May Predict for Overall Survival in Prostate Cancer

Share this content:
Researchers assessed CTC and PSA response endpoints in 6081 patients enrolled in 1 of 5 randomized phase 3 studies.
Researchers assessed CTC and PSA response endpoints in 6081 patients enrolled in 1 of 5 randomized phase 3 studies.

Circulating tumor cell (CTC) counts correspond with overall survival (OS) among patients with early-phase metastatic castration-resistant prostate cancer (mCRPC), according to a study published in the Journal of Clinical Oncology.1

Treatment modalities are changing rapidly for patients with mCRPC, creating a need for more robust and reliable endpoints to determine the benefit of clinical interventions. It is unclear, furthermore, whether prostate-specific antigen (PSA) testing is still the best surrogate marker for survival.

For this study, researchers assessed CTC and PSA response endpoints in 6081 patients enrolled in 1 of 5 prospective randomized phase 3 studies: COU-AA-301 (ClinicalTrials.gov Identifier: NCT00638690), AFFIRM (ClinicalTrials.gov Identifier: NCT00974311), ELM-PC5 (ClinicalTrials.gov Identifier: NCT01193257), ELM-PC4 (ClinicalTrials.gov Identifier: NCT01193244), and COMET-1(ClinicalTrials.gov Identifier: NCT01605227).

Eight CTC and PSA response measures were investigated: CTC0 (patients with a CTC count of 1 or higher at baseline and 0 at week 13), CTC conversion (CTCconv; patients with a CTC of count 5 or higher at baseline and 4 or fewer at week 13), and 3 measures of percent change for CTC (CTC counts of 5 or greater at baseline and a 30%, 50%, or 70% decline from baseline to week 13, respectively) and PSA (PSA level 5 ng/mL and greater at baseline and a 30%, 50%, or 70% decline from baseline to week 13, respectively).

CTC0 and CTCconv were the most useful markers for differentiating survival outcomes between responders and non-responders at week 13. The average weighted c-indices for CTC0 and CTCconv were 0.81 and 0.79, respectively. Weighted c-indices ranged from 0.5 to 1.0; a higher index indicated a greater probability of longer survival for patients who responded to treatment.

Having no detectable CTCs after treatment or converting from a higher level to fewer than 5 were better for discriminating patient survival compared with the percent change measures for CTC or PSA. Both measures allowed for broad eligibility, but more patients were evaluable with CTC0 (75%) vs CTCconv (51%).

The authors concluded that CTC0 provides “objective and reliable evidence that the therapy being administered has altered the patient's prognosis in a favorable way. Taken together, the results of this study support the use of CTC0 as a response end point in early-phase clinical trials.”

Reference

  1. Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trialsJ Clin Oncol. 2017 Dec 22. doi: 10.1200/JCO.2017.75.2998 [Epub ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs